Adage Capital Partners’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Adage Capital Partners’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,200,000	Closed	-$21.3M	–	786
2018 Q3	$21.3M	Buy	1,200,000 +450,000	+60%	+$7.73M	0.05%	384
2018 Q2	$10.3M	Sell	750,000 -750,000	-50%	-$8.9M	0.02%	560
2018 Q1	$13.6M	Buy	1,500,000 +1,378,000	+1,130%	+$7.6M	0.03%	494
2017 Q4	$522K	Buy	+122,000	New	+$581K	﹤0.01%	688
2014 Q2	–	Sell	-619,559	Closed	-$14.8M	–	769
2014 Q1	$14.8M	Buy	+619,559	New	+$8.98M	0.04%	432

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $830M AUM 21.8% 1-Year Est. Return

Adage Capital Partners's ECYT Position: Q4 2018 in Review

Adage Capital Partners sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 1,200,000 shares — an estimated $21.3M sold.

Adage Capital Partners first reported a position in ECYT in Q1 2014 and held it in 5 quarters. The position peaked at $21.3M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Adage Capital Partners reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Adage Capital Partners sold 1,200,000 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $21.3M.
Adage Capital Partners first reported a position in Endocyte, Inc. Common Stock in Q1 2014 and held it in 5 quarters.
Adage Capital Partners's Endocyte, Inc. Common Stock position peaked at $21.3M in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Adage Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.